08:30 - 12:00 |
 |
The DDL Incubator New for DDL2026 As an added value benefit to those attending DDL 2026 in person, we are delivering a session dedicated to exploring the funding options available to start-ups, biotech founders and similar stakeholders. This session is free to attend but you must register separately. |
|
11:00 |
 |
DDL2026 Registration Poster Hall open for refreshments Exhibition Hall open for refreshments |
|
12:00 - 13:30 |
 |
Networking Lunch in the Exhibition Hall and Poster Hall Network with delegates and view the industry exhibition and poster exhibition. Lunch is served in the exhibition hall and the poster hall. |
|
12:00 - 13:00 |
 |
The DDL New Researcher Networking Lunch Networking Session – for new and early career scientists and PhD students only. Lowther Meeting Room, Level -1 You must register to attend this session. |
|
13:30 |
 |
Conference Opens Welcome by |
|
13:45 |
 |
Development Challenges with Inhaled Formulations The DDL Lecture is a prestigious accolade bestowed on individuals who have contributed much to the field of respiratory science. |
|
14:15 - 15:10 |
SESSION 1 – ADVANCES IN SOLID-STATE FORMULATION |
||
14:20 |
 |
Structure of biologics solid formulations from NMR |
|
14:45 |
 |
Analysing the architecture of engineered particles through nanoscale X-ray Computed Tomography |
|
15:10 - 16:30 |
 |
Refreshment Break Explore the exhibition stands and network with delegates Manned Poster Session – JUDGING The poster exhibition is on Level -2. Poster presenters will be interviewed by the DDL Judges to be considered for the Best Academic and Best Industry Poster. Please allow judges to take priority in talking to the authors during this session. Another manned poster session is scheduled during the Thursday morning refreshment break |
|
16:30: - 17:40 |
SESSION 2 -INHALED ANTIMICROBIALS |
||
16:35 |
 |
Harnessing Artificial Intelligence to reshape research in antimicrobial resistance and infectious diseases |
|
17:00 |
 |
A quantitative systems pharmacology/PKPD perspective on when inhaled administration offers advantages over systemic administration |
|
17:25 |
 |
Spray-dried inhalable powders of an Aspergillus fumigatus sphingosine-1-phosphate lyase inhibitor for cystic fibrosis airways Spray-dried inhalable powders of an Aspergillus fumigatus sphingosine-1-phosphate lyase inhibitor for cystic fibrosis airways |
|
17:40 - 20:00 |
 |
Welcome Drinks Reception Networking across the conference centre, with drinks and canapes in the exhibition hall. |
|
17:40 - 18:30 |
|
The New Researcher Network – Careers Uncorked: A Drink with My Younger Self For new and early career researchers and PhD Students only. With invited guests. Lowther Meeting Room, Level -1 You must register to attend this session. |
08:00 - 09:00 |
|
Registration and Refreshments Explore the exhibition stands and the poster exhibition and network with delegates |
|
09:00 |
Winner of The DDL2026 Emerging Scientist Award Announced The winner of this award will be announced live on stage and will present their research. This award recognises significant scientific accomplishment or innovation during the early stages of an individual’s career in inhalation science. |
||
09:05 |
 |
The DDL2026 Emerging Scientist Winner’s Presentation |
|
09:35 - 12:20 |
SESSION 3 – DIGITAL DRUG DELIVERY (dDDL) |
||
09:40 |
 |
Blind Spots for Understanding Drug Absorption to Systemic Circulation: Complex Routes and insights from Deconvolution
|
|
10:05 |
 |
Development of a physiologically based pharmacokinetic model for intranasal ondansetron |
|
10:20 - 11:40 |
|
Refreshment Break Explore the exhibition stands and network with delegates Manned Poster Session The poster exhibition is on Level -2. Authors will be at their posters to discuss them with the attendees. |
|
11:40 - 12:20 |
SESSION 3: DIGITAL DRUG DELIVERY (dDDL) – CONTINUED |
||
11:40 |
 |
Towards In-Silico Clinical Trials: Assessing Bioequivalence of Dry Powder Inhalers Based on Regional Lung Deposition |
|
11:55 |
 |
From Design to Delivery: How Digital Innovation Is Reshaping and Accelerating Respiratory Trials |
|
12:20 - 14:00 |
|
Networking Lunch in the Exhibition Hall and Poster Hall Network with delegates, visit the exhibition stands and view the conference posters. Lunch is served in the exhibition hall and poster hall. |
|
14:00 - 15:20 |
SESSION 4: THE PAT BURNELL YOUNG INVESTIGATOR AWARD Finalists present their work and are judged by the DDL Organising Committee The winner of the competition will be announced following the day’s lectures in the Pentland Auditorium. This award recognises the vision of Pat Burnell and has been designed to encourage junior researchers from either academia or industry to present their work at the DDL Conference. |
||
14:05 |
 |
Droplet Clustering in HFA-152a Metered Dose Inhalers |
|
14:20 |
 |
Exposure of dry powder aerosols to macrophages co-cultured with alveolar epithelia Mykaella Mestre, Hovione Farmaciencia S.A. and Institute for Bioengineering and Biosciences |
|
14:35 |
 |
From Broad Activation to Precision Strike: A Pulmonary-Delivered Hybrid OMV-mRNA Platform for Lung Cancer Immunotherapy |
|
14:50 |
 |
Development of a liposomal Cannabidiol formulation for enhanced bioavailability: A comparative evaluation of oral, intranasal, and pulmonary delivery |
|
15:05 |
 |
MLGold: A CFD-Informed Machine Learning Framework for Patient-Specific Inverse Design of Targeted Aerosol Delivery |
|
15:20 - 16:20 |
|
Refreshment Break Explore the exhibition stands and the poster exhibition and network with delegates |
|
16:20 - 17:15 |
SESSION 5 – PROPELLANTS, PLANET & PATIENTS: CLINICAL NEEDS AND ADVOCACY |
||
16:25 |
 |
Transitioning pMDIs to Low-GWP Propellants: Addressing formulation challenges and navigating regulatory pathways |
|
16:50 |
 |
Next-Generation Propellants in pMDIs: Why Valve Design Becomes a Critical Performance Driver |
|
17:15 |
|
Awards Ceremony Join us in the Pentland Auditorium as we announce the winners of:
|
|
17:45 |
|
Networking Drinks Reception Networking across the conference centre, with drinks and canapes in the exhibition hall. |
08:30 - 09:30 |
|
Morning Refreshments Explore the exhibition stands and the poster exhibition and network with delegates before the lecture programme begins for the final day |
|
09:30 - 12:30 |
SESSION 6 – SITE-SPECIFIC AEROSOL DELIVERY |
||
09:35 |
 |
Akkermansia Muciniphila: A Mucin-Degrading Next-Generation Probiotic for Pulmonary Drug Delivery |
|
09:50 |
 |
Feasibility of delivering mRNA-LNP via acoustic nebulisation: In vitro and in vivo assessment |
|
10:05 |
 |
A Lipid Nanoparticle Platform for Pulmonary Macrophage Targeting: New Opportunities for Lung-Directed Therapies |
|
10:30 - 11:40 |
|
Refreshment Break Explore the exhibition stands, view the conference posters and network with delegates |
|
11:40 |
SESSION 6 : SITE-SPECIFIC AEROSOL DELIVERY – CONTINUED |
||
11:40 |
 |
Considerations Regarding the Use of Cascade impactors to Aid in Site-Specific Delivery of Dry Powders in the Respiratory Tract |
|
12:05 |
 |
Towards Standardised Compendial Testing of Nasal Products: Multi-Laboratory Evaluation of the Kiel Nasal Inlet for Assessment of the %<10 µm Fraction |
|
12:20 |
|
Closing remarks |
Formulation Science |
|||
|---|---|---|---|
01 |
 |
Understanding the N-acetylcysteine properties to exert its anti-biofilm efficacy against Pseudomonas aeruginosa and to be respirable
Imane Abidli , Université Libre de Brussels (ULB) and University of Mons (UMons) |
|
02 |
 |
Transforming Dry Water to Dry Water Drug Delivery – Understanding Model Drug Release Profiles |
|
03 |
 |
In Vitro Characterisation of Nebulised Antisense Oligonucleotide (ASO) for Inhalation Delivery |
|
04 |
 |
The Kinetics of Drug Release from Inhalable Alginate-Based Bioaerogel Microparticles |
|
05 |
 |
Using Small-Angle Neutron Scattering (SANS) to Examine Structural Changes of RNA Lipid Nanoparticles Following Nebulisation |
|
06 |
 |
Spray-drying of Dry Powder Exosome-based Therapies for Targeted Drug Delivery |
|
07 |
 |
Development of Spray-Dried siRNA-Loaded MC3 Lipid Nanoparticle Powders for Pulmonary Delivery |
|
08 |
 |
Development and Optimization of an Inhalable Osimertinib-Loaded Liposomal Formulation for Pulmonary Delivery |
|
09 |
 |
Engineering an HPβCD-Stabilized Sorafenib Liposomal Dry Powder for Potential Pulmonary Delivery |
|
10 |
 |
Advanced antifungal therapy: Trojan particle-based inhalation of Itraconazole |
|
11 |
 |
In vitro optimisation of pulmonary delivery of synthetic anion transporters to cystic fibrosis airway epithelia using lipid-polymeric nanoparticles
Yanira Manzanares Fornies , Macquarie University and University of Bristol |
|
12 |
 |
Spray-Dried Microparticles Incorporating Nanocrystals of a Lipophilic Drug |
|
13 |
 |
Spray-dried chitosan-based microcapsules for pH-responsive delivery of resveratrol in pulmonary arterial hypertension |
|
14 |
 |
Systematic Characterization of Candidate Fusiogenic Liposomes for Inhalation |
|
15 |
 |
A Lung-Surfactant-Anchored Peptide-Drug Conjugate Platform Enabling Extended Pulmonary Residence Time and Tunable Systemic Pharmacokinetics |
|
16 |
 |
Spray-Dried Liquid Crystalline Microparticles for Targeted Sustained Pulmonary Delivery of Afatinib: Design Optimization and In vitro evaluation |
|
Devices & Aerosols |
|||
|---|---|---|---|
17 |
 |
Impact of Device Resistance and Inhalation Orientation on the Delivered Dose of an Open–Inhale–Close Dry Powder Inhaler Being Used for a Systemic Drug Delivery Application
Murat Ali , Phillips Medisize Global Innovation and Development Centre |
|
18 |
 |
In Vitro Evaluation of the Aerodynamic Performance of an Innovative Active pDPI to Overcome Flow Dependence Limitations |
|
19 |
 |
Investigation of the Impact of Flow Rate Acceleration on Dose Aerosolization and Measured Aerodynamic Particle Size Distribution Using Two Dry Powder Inhalers of Differing Device Resistances |
|
20 |
 |
Towards A Saturation Based Description of Impact-Induced API detachment in Carrier-Based Dry Powder Inhalers |
|
21 |
 |
Developing an Ultra-High Payload Nose-to-Lung DPI Device: The Design Journey |
|
22 |
 |
Evaluation of Aerosolisation Performance of a Model Protein Delivered via the Sunriser® DPI |
|
23 |
 |
An innovative pMDI Enhancer platform: Usability, acceptability and early tolerability of A202 in adults with asthma or COPD, interim analysis of a single-arm study
Zahir Jaffer , Aerodel Technology Innovations Private Limited |
|
24 |
 |
Experimental and Numerical Investigation of the Impact of Design Features on the Performance of Breezhaler |
|
25 |
 |
Influence of Inhaler Resistance and Throat Geometry on Aerodynamic Performance of a Spray-Dried Antibiotic Formulation |
|
26 |
 |
The 1nhaler Platform Device: Development and Optimisation of the First Pop-Up Single Dose DPI |
|
27 |
 |
Selection of the Optimal Resistance in RS01 for Robust Aerosol Performance of Controlled-Release Budesonide Powder for Inhalation for Chronic Obstructive Inflammatory Respiratory Diseases Patients. |
|
28 |
 |
High-Throughput Electrospraying (Electronebulization) for the Generation of Bioactive Inhalable Monoclonal Antibody Particles
Jose M. Lagaron , Novel Materials and Nanotechnology for Health Applications group at CSIC |
|
29 |
 |
Quantification of amorphous lactose in micronized lactose for inhalation |
|
30 |
 |
An Orthogonal MDRS and SEM-EDX Workflow for Comprehensive Characterisation of Foreign Particulates in Mometasone Furoate pMDI Products |
|
31 |
 |
Single Particle Measurements of Geometric and Aerodynamic Size, Morphology and Hygroscopicity |
|
32 |
 |
Correlating aerosol plume structure to particle deposition using optical techniques |
|
33 |
 |
Engineered Particles, DPIs, and Particle Bounce: Considerations for Mass Loading and Cascade Impactor Coating Selection |
|
34 |
 |
Assessment of bounce effects in the Next Generation Impactor – comparison between experimental and modeled size distributions |
|
35 |
 |
Low Effort, High Dose: An In Vitro Investigation of the Flow Rate Dependency of Total and Regional Lung Doses for Spray Dried Powders Designed for Inhalation |
|
36 |
 |
Exploring Morphometric Descriptors for Rapid Screening of Respirable Spray-Dried Powders |
|
37 |
 |
Effect of Primary Particle Size and Particle Aggregation Level on Aerosol Performance of a Nebulized Antimicrobial Suspension |
|
38 |
 |
Investigating the Impact of NGI Cup Depth, Flow Rate and Formulation Composition on Aerosol Deposition and Particle Re-entrainment of High-Payload Spray-Dried Protein Powders |
|
39 |
 |
Effective Comparison of Aerodynamic Particle Size Distribution Data Across Different NGI Airflow Rates Using Fusion Inhaler TestingTM (FIT) Data Evaluation Software |
|
Powder Inhalers |
|||
|---|---|---|---|
40 |
 |
Nitrogen-Assisted Particle Fluidisation for Dry Coating of High-Dose Inhalable Powders: Impact on Particle Micrometrics |
|
41 |
 |
Assessment of the Effect of Formulation Composition and Manufacturing Environmental Conditions on the In Vitro Performance of a Dual Drug Capsule-Based Dry Powder Inhaler |
|
42 |
 |
Co-jet milled Ceftazidime pentahydrate inhalable dry powders as antimicrobial therapy against Pseudomonas aeruginosa pulmonary infections |
|
43 |
 |
From Particle Engineering to Lung Delivery: Spray-Coat as High Load and High-Performance Inhalation Therapies Enabler |
|
44 |
 |
Delivery System Options for Inhaled Spray-Dried GLP-1 Peptides – A Comparison of Stability Profiles for Capsule Versus Blister Devices |
|
45 |
 |
Evaluation of Particle Size Reduction Technologies for Ensifentrine: Why Jet Milling Remains the Most Suitable Approach |
|
46 |
 |
Influence of Particle Morphology on Powder Filling with a Volumetric Drum Dosing Device |
|
47 |
 |
Engineering a Spray-Dried Tirzepatide Dry Powder for Pulmonary Delivery: Solid-State Characterisation and Aerosol Performance |
|
48 |
 |
Effect of repeated processing with the Vibro-Pelletiser 2.0 on the properties of softpellets |
|
49 |
 |
Dissolution Assessment of Resonant Acoustic Mixing and High Shear Dry Powder Inhaler Blends |
|
50 |
 |
Characterising physical stability of a dry powder inhaler formulation and integrating predictive modelling across a range of temperature and humidity conditions. |
|
51 |
 |
Effect of protein concentration on the stability and aerosolisation of Trehalose/Pullulan/Leucine formulated particles prepared by spray drying |
|
52 |
 |
Adhesive Mixtures of iBCS Class II drugs: Influence of Lactose fines on dissolution |
|
53 |
 |
Investigation of Stability and Biological Activity of Spray-Dried Monoclonal Antibody Formulations for Pulmonary Delivery
Zeina Kassem , University of West London/University of College London |
|
54 |
 |
Effects of leucine and relative humidity on bioactivity and aerosolization properties of spray-dried trypsin formulations
Professor Anna Millqvist Fureby , Dept of Process and life science engineering, Lund Univeristy |
|
55 |
 |
Developing Stable Inhalable Immunoglobulin Y Powder Formulations for Pulmonary Delivery |
|
56 |
 |
Synergistic Effect of Polysorbate 20 and L-Leucine on Particle Morphology and Aerodynamic Performance |
|
57 |
 |
Evaluation of Carrier Particle Classification by the Quattrii Dry Powder Inhaler |
|
58 |
 |
Tiotropium DPI Formulations: Where are the hidden differences? |
|
Liquid Inhalers |
|||
|---|---|---|---|
59 |
 |
Assessment of Spatial Evolution of pMDI Plume Temperature in an Anatomical Throat Model |
|
60 |
 |
Engineered Hydrophilic Polymeric Microparticles to Improve Suspension Stability in Low-GWP pMDIs |
|
61 |
 |
Charged Interactions: The Role of Co Solvent Concentration in the Electrostatic Behaviour of HFA 152a and HFA 134a Salbutamol Formulations |
|
62 |
 |
Simulating Low-GWP Propellant Evaporation: the Effect of Humidity and Ethanol Composition |
|
63 |
 |
Characterizing the Aerosol Half-Life and Delivery Efficiency of a Low-GWP Propellant pMDI: Effects of Inhalation Delay with an Antistatic Spacer |
|
64 |
 |
Next Generation Assessment: In Vitro Assessments to Support U.S. FDA Updates on In Vitro Bioequivalence Assessments for Metered Dose Inhalers (MDIs) |
|
65 |
 |
Defying Dipole Moment: Electronic Contributions to the Enhanced Adsorption of HFO-1234ze(E) on Aluminium Surfaces |
|
66 |
 |
Can Nozzle Geometry Compensate for Increased Formulation Viscosity in a Soft Mist Inhaler? |
|
67 |
 |
Application of Design of Experiments for the development of a semi-automated method for pMDIs using next generation propellants |
|
68 |
 |
Refining Aerosol Characterisation Methods for Soft Mist Inhalers |
|
69 |
 |
Establishing a Biologics Design Space for Soft Mist Inhaler Delivery: Feasibility of Softhaler® Across Increasing Molecular Weight and Structural Complexity |
|
70 |
 |
Nintedanib High Dose Suspension Based pMDI Drug Delivery Using Next Generation Propellant |
|
71 |
 |
Beyond Fill Volume: Assessing Nebulizer Performance by Drug Usage Efficiency |
|
72 |
 |
Study on the Airflow Characteristics of a High-Delivery-Efficiency Mesh Nebulizer Aerosol Chamber Based on Computational Fluid Dynamics (CFD) |
|
73 |
|
Study on Vibration-Induced Free-Surface Fluctuation and Air Entrainment Mechanism of a Micro-Mesh Nebulizer Based on the Volume of Fluid Model |
|
74 |
|
An In Vitro Comparison of Vibrating Mesh and Jet Nebulisers: Aerosol Delivery and Post-Nebulisation Characteristics of Antibiotic-Loaded Liposomes |
|
75 |
 |
Development of a Physiologically Relevant Next Generation Impactor (NGI) Method for Soft-Mist Inhalers (SMI) |
|
76 |
 |
Development of a novel hands-free vibrating mesh nebulizer for nasal administration |
|
Nasal Delivery |
|||
|---|---|---|---|
77 |
 |
Investigating the Influence of Flow Rate Conditions and Airway Surface Coating on Regional Deposition of a Cromolyn Sodium Spray in the Alberta Idealized Nasal Inlet |
|
78 |
 |
Development of a Novel Spray-Dried Platform for Nasal Delivery of Sumatriptan: Addressing the Challenge of Low Glass Transition Temperature |
|
79 |
 |
Development of Peptide Nasal Powders by Moisture-Activated Dry Granulation |
|
80 |
 |
Tuning Nasal Spray Performance by Formulation Design |
|
81 |
 |
Thermoresponsive Nasal Formulations: Evaluation of Rheology, Spray Characteristics, and Regional Deposition to Develop a Clinically Relevant Nasal Product. |
|
82 |
 |
Targeting the Olfactory Region: A Formative User Study Using an Average-Geometry Nasal Cast and Human Head Model |
|
83 |
 |
Deposition Studies of Ibuprofen/Zolmitriptan loaded Nanostructured Lipid Carriers to Maximise Olfactory Targeting in Acute Migraine Therapy |
|
84 |
 |
Overcoming the 2D analytical blind spot: AI-directed MDRS (DeepMorph) toward Q3 Microstructural Equivalence of Nasal Suspension Products |
|
85 |
 |
Development of Gabapentin Dry Powder for Nasal Drug Delivery |
|
86 |
 |
Nasal Powder Filling: A comparison of Two Filling Technologies for the DriDose® Intranasal Delivery System |
|
87 |
 |
Nasal Drug Delivery Using β-Lactoglobulin-Based Dry Powder Formulations |
|
88 |
 |
Development of Oligonucleotide Powders for Intranasal and Pulmonary Delivery
Antonia Zapata del Baño , Nanopharm, an Aptar Pharma Company |
|
89 |
 |
Epidermal growth factor-loaded chitosan nanoparticles for enhanced nasal epithelial wound repair
Dr Hanieh Gholizadeh , Woolcock Institute of Medical Research |
|
90 |
 |
Quantifying the Effect of Mucoadhesive Excipients on Nasal Powder Drug Release in Native Porcine Mucus |
|
91 |
 |
Intranasal delivery of semaglutide using a thermoresponsive nanogel platform: formulation development, epithelial transport and in vivo retention
Tanisha Khan , Macquarie University and Woolcock Institute of Medical Research |
|
92 |
 |
Design and Evaluation of a Brain-Targeted Nanoparticulate System for Intranasal Delivery of Lemborexant in the Management of Sleep Disturbances |
|
93 |
 |
Nose-to-Brain RNA Delivery via RVG-Functionalized Extracellular Vesicle-Mimetic Liposomes |
|
94 |
 |
Effect of Insertion Angle and Depth on Regional Nasal Deposition of Baqsimi Dry Powder Nasal Spray Using the Proveris Nasal Cast |
|
Modelling & Biologics |
|||
|---|---|---|---|
18 |
|
||
95 |
 |
Computational Fluid Dynamics Models of Nasal Delivery: Bayesian Optimisation of Spray Characteristics to Maximise Aerosol Deposition Uniformity and Sensitivity Analysis of Patient Usage |
|
96 |
|
In silico tools for understanding aerosol delivery: formulation, aerosol dynamics and lung deposition |
|
97 |
|
Predictive Modelling of Droplet and Particle Size Distributions for Spray-Dried Intranasal Powders |
|
98 |
 |
AI-Ready Single-Cell Phenotyping Reveals Species Specific Foamy Macrophage Responses to Inhaled Medicines |
|
99 |
 |
Comparison of Regional Lung Deposition from Computational Fluid Dynamics Simulations with Planar Gamma Scintigraphy Using a Common Regional Deposition Analysis |
|
100 |
 |
Modelling and Prediction of Stability Trends in Aerodynamic Particle Size Distribution (APSD) of Dry Powder Inhalers (DPIs) |
|
101 |
 |
Sensitivity of Particle Deposition Predictions to Transport Model Selection in a Rat Airway CFD Model |
|
102 |
 |
Studying Nasal Spray Particle Deposition through Mixed Experimental and Computational Fluid Dynamics |
|
103 |
 |
Development of inhalable LNPs for the pulmonary delivery of anti-miR-34a |
|
104 |
 |
Optimisation of Spray Drying Process Parameters to Produce Inhalable Monoclonal Antibody (mAb) Powders |
|
105 |
 |
Bacteriophage aerosolization with the Kolibri™ Mesh Nebulizer: infectivity retention and aerodynamic deposition characterization |
|
106 |
 |
The Potential of Rayleigh Aerosols for Pulmonary Delivery of LNP-mRNAs |
|
107 |
 |
Development of Spray-Dried and Freeze-Dried Phage Formulations |
|
108 |
 |
High-Concentration Immunoglobulin G Delivery Using the FOX™ Vibrating Mesh Nebuliser |
|
109 |
 |
Encapsulation of the siRNA Asvasiran in Lipid Nanoparticles for Delivery via the Softhaler® Soft-Mist Inhaler |
|
110 |
 |
Evaluation of Permeation Enhancers for Pulmonary Delivery of High Molecular Weight Biologics Across Epithelial Models |
|
111 |
 |
Integrating Device and Formulation Design for Optimal Performance of Inhaled Biologics using the AdheResp® Breath-Actuated Nebulizer platform |
|
Pre-clinical & Clinical |
|||
|---|---|---|---|
18 |
 |
Anežka Klouček , 1st Faculty of Medicine, Charles University |
|
112 |
 |
Evaluation of an Intermittent Nebulization Mode Converter Under Low-Fill, Dose-Conserving Salbutamol Challenge Conditions |
|
113 |
 |
Enhancing Paediatric Inhalation Efficiency: The Impact of High-Concentration Nanosuspensions and Breath-Actuated Technologies with Long-bolus Breathing |
|
114 |
 |
Non-invasive synthetic surfactant dry powder aerosol delivery for the treatment of respiratory distress syndrome |
|
115 |
 |
Advancements in Fire-Related Toxic Gas Detection and Prophylactic Strategies: A Focus on Cyanide Concentration Analysis and Antidote Efficacy in Controlled Smoke Inhalation Models |
|
116 |
 |
Poorer Asthma Control After Inhaler Device Switching Between Pressurised Metered-Dose and Dry Powder Inhalers: A Retrospective Primary Care Cohort Study in England |
|
117 |
 |
High-Dose Inhaled Doxycycline via the Orbital™ Inhaler |
|
118 |
 |
In-silico study using the Ebenbuild Twinhale model on the benefits of a monodisperse aerosol with tuneable particle size as generated by the Gilbert Smart Precision Inhaler |
|
119 |
 |
Inhalable Peptide-Based Host-Directed Therapy for Matrix Metalloproteinase Inhibition and Attenuation of Chronic Lung Immunopathology
Agrim Jhilta , Instutute of Nano Science and Technology, India |
|
120 |
|
Effect of Human Actuation and Device Design on Nasal Spray Performance: Comparing Soft Mist and Conventional Metered-Dose Technologies |
|
121 |
 |
Preclinical study of a new synchronized mesh (A-VMN) nebulizer for mechanical ventilation using ex vivo pig and human lung models |
|
122 |
 |
Air-liquid interface culture of precision-cut lung slices for investigating the safety and efficacy of inhalable drug formulations |
|
123 |
 |
Evaluation of the Discriminatory Ability of Three Dissolution Methods with Different Sample Collection and Dissolution Apparatus |
|
124 |
 |
Characterisation of Primary Human 3D Bronchial Tissues for Pre-clinical Drug Aerosol Testing in the NAVETTA Horizontal Flow Exposure Chamber
Dr. Sandra Verstraelen , Flemish Institute for Technological Research (VITO) |
|
125 |
 |
From Bronchi to Alveoli: The Impact of Biorelevant Media on OIDPs Dissolution in Health and Disease |
|
126 |
 |
Linking Aerodynamic Aerosol Size Fractions with Stage-Dependent Cellular Responses Using the Next Generation Impactor |
|
127 |
 |
Assessment of the Effect of Sample Collection on the Dissolution Profile of Fluticasone Furoate Delivered by a Dual Blister Dry Powder Inhaler |
|
128 |
 |
Aerosol dynamics in rat directed flow systems influence accuracy of predicted lung dose on toxicology studies |
|
129 |
|
Pulmonary and Systemic Exposure to Cannabidiol in Healthy and ALI Rats
Anežka Klouček , 1st Faculty of Medicine, Charles University |
|